Methods and Compositions Comprising Hyaluronan for Enhancing Bone Marrow Cell Therapy

Abstract

Disclosed herein are methods and compositions for treating cardiovascular disease and damaged cardiac tissue which employ at least one hyaluronan (HA) compound and one or more cells selected from the group consisting of stem cells, precursor cells, progenitor cells, committed cells, mature somatic cells, and recombinant cells.

What is claimed is: 
     
         1 . A composition for treating a cardiovascular disease or damaged cardiac tissue in a subject comprising:
 at least one hyaluronan (HA) compound and one or more cells selected from the group consisting of stem cells, precursor cells, progenitor cells, committed cells, mature somatic cells, and recombinant cells,   wherein the molecular weight of the HA is less than 1500 kDa, the amount of the at least one HA compound is about 0.01 to about 10 mg/kg body weight of the subject and the amount of the one or more cells is about 1×10 4  to about 1×10 8  cell/kg body weight of the subject.   
     
     
         2 . The composition of  claim 1 , wherein the at least one HA compound is about 1-5% by weight of the composition; and
 wherein the at least one HA compound and the one or more cells is formulated as a single dosage volume of about 100 to about 2000 μL.   
     
     
         3 . The composition of  claim 1 , wherein the one or more cells are hematopoietic stem cells, mesenchymal stem cells, endothelial stem cells, and/or blood cells. 
     
     
         4 . The composition of  claim 1 , wherein the one or more cells are autologous cells to the subject or allogeneic cells from one or more donors. 
     
     
         5 . The composition of  claim 1 , wherein the one or more cells are myofibroblasts, bone marrow cells, blood cells, adipose tissue-derived cells, placental cells, umbilical cord cells, umbilical cord blood cells, amniotic fluid cells, cardiomyocyte-like cells, pluripotent stem cell-derived cells, or somatic cell-derived stem/progenitor cells. 
     
     
         6 . The composition of  claim 1 , which is formulated for administration to the myocardium of a heart by thoracotomy, cardiac catheterization, echo-guided or endoscope-assisted injection, or a syringe. 
     
     
         7 . The composition of  claim 1 , further comprising at least one supplementary active compound. 
     
     
         8 . The composition of  claim 1 , wherein the composition does not comprise plasma nor plasma product.